The stock of Eterna Therapeutics Inc (ERNA) has seen a 4.85% increase in the past week, with a -44.92% drop in the past month, and a -77.71% decrease in the past quarter. The volatility ratio for the week is 15.87%, and the volatility levels for the past 30 days are at 18.27% for ERNA. The simple moving average for the past 20 days is -10.05% for ERNA’s stock, with a -81.67% simple moving average for the past 200 days.
Is It Worth Investing in Eterna Therapeutics Inc (NASDAQ: ERNA) Right Now?
The 36-month beta value for ERNA is at 4.30. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ERNA is 48.88M, and currently, shorts hold a 1.24% of that float. The average trading volume for ERNA on December 27, 2024 was 723.43K shares.
ERNA) stock’s latest price update
The stock of Eterna Therapeutics Inc (NASDAQ: ERNA) has increased by 13.69 when compared to last closing price of 0.25. Despite this, the company has experienced a 4.85% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.
ERNA Trading at -58.46% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.22% of loss for the given period.
Volatility was left at 18.27%, however, over the last 30 days, the volatility rate increased by 15.87%, as shares sank -39.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.28% lower at present.
During the last 5 trading sessions, ERNA rose by +4.85%, which changed the moving average for the period of 200-days by -88.54% in comparison to the 20-day moving average, which settled at $0.3147. In addition, Eterna Therapeutics Inc saw -84.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- -0.98 for the gross margin
The net margin for Eterna Therapeutics Inc stands at -75.14. The total capital return value is set at 8.39. Equity return is now at value -1154.18, with -149.86 for asset returns.
Based on Eterna Therapeutics Inc (ERNA), the company’s capital structure generated -2.45 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at -0.71. The interest coverage ratio of the stock is -5.12.
Currently, EBITDA for the company is -19.93 million with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 73.29. The receivables turnover for the company is 3.2for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.48.
Conclusion
In conclusion, Eterna Therapeutics Inc (ERNA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
